Biogen

Biogen logo
🇺🇸United States
Ownership
Private
Established
1978-01-01
Employees
7.5K
Market Cap
$29.6B
Website
https://www.biogen.com
Introduction

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2018-10-23
Last Posted Date
2021-05-25
Lead Sponsor
Biogen
Target Recruit Count
24
Registration Number
NCT03716570
Locations
🇯🇵

Research Site, Kodaira-shi, Tokyo-To, Japan

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

First Posted Date
2018-10-02
Last Posted Date
2023-12-13
Lead Sponsor
Biogen
Target Recruit Count
35
Registration Number
NCT03692910
Locations
🇺🇸

Sage Investigational Site, Richardson, Texas, United States

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-10-01
Last Posted Date
2024-06-12
Lead Sponsor
Biogen
Target Recruit Count
585
Registration Number
NCT03689972
Locations
🇧🇪

CHU de Tivoli, La Louvière, Belgium

🇺🇸

MS Center of California, Laguna Hills, California, United States

🇺🇸

UCI MIND, Irvine, California, United States

and more 104 locations

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2018-09-14
Last Posted Date
2023-11-29
Lead Sponsor
Biogen
Target Recruit Count
581
Registration Number
NCT03672175
Locations
🇺🇸

Site Investigational Site, Decatur, Georgia, United States

🇺🇸

Sage Investigational Site, Charlottesville, Virginia, United States

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

First Posted Date
2018-09-10
Last Posted Date
2022-10-18
Lead Sponsor
Biogen
Target Recruit Count
2274
Registration Number
NCT03662919
Locations
🇫🇷

Research Site, Toulon, Provence-Alpes-Côte d'Azur, France

🇫🇷

Research Site 2, La Rochelle, Nouvelle-Aquitaine, France

🇫🇷

Research Site 3, Paris, Ile De France, France

and more 8 locations

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

First Posted Date
2018-08-21
Last Posted Date
2021-09-16
Lead Sponsor
Biogen
Target Recruit Count
52
Registration Number
NCT03639987
Locations
🇺🇸

Neurology Center of North Orange County, Fullerton, California, United States

🇺🇸

Pacific Research Network, Inc, San Diego, California, United States

🇺🇸

Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, United States

and more 18 locations

802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2018-08-20
Last Posted Date
2023-05-06
Lead Sponsor
Biogen
Registration Number
NCT03637387

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Phase 1
Completed
Conditions
Interventions
First Posted Date
2018-08-10
Last Posted Date
2022-01-14
Lead Sponsor
Biogen
Target Recruit Count
106
Registration Number
NCT03626012
Locations
🇬🇧

Research Site, London, United Kingdom

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2018-06-29
Last Posted Date
2020-12-11
Lead Sponsor
Biogen
Target Recruit Count
109
Registration Number
NCT03573505
Locations
🇬🇧

Research Site, Leeds, West Yorkshire, United Kingdom

🇺🇸

Reserach Site, Houston, Texas, United States

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111

Phase 2
Completed
Conditions
Interventions
First Posted Date
2018-04-25
Last Posted Date
2024-02-23
Lead Sponsor
Biogen
Target Recruit Count
66
Registration Number
NCT03507686
Locations
🇩🇪

Research Site, Tübingen, Germany

© Copyright 2024. All Rights Reserved by MedPath